Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
Spear
G T
GT
Olinger
G
G
Sullivan
B L
BL
Landay
A L
AL
Kessler
H
H
Connick
E
E
Kuritzkes
D
D
St Clair
M
M
Spritzler
J
J
Wu
H
H
Lederman
M M
MM
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003171:Complement Pathway, Classical; D003165:Complement System Proteins / Q000032:analysis*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015483:HIV Antibodies / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015483:HIV Antibodies; D015488:HIV Antigens; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D003165:Complement System Proteins; D019438:Ritonavir